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Abstract of the thesis of
Steven D. Ebers
Department of Physiology
THE EFFECT OF TESTOSTERONE ON LEYDIG CELL DEVELOPMENT IN MALE
YHR+ MICE
Mentor: Dr. Prema Narayan

Leydig cells (LC) are specialized cells in the testis that develop during puberty
and are responsible for producing testosterone. Luteinizing Hormone (LH) and
testosterone are important for LC development. Binding of LH to its receptor (LHR)
initiates the production of testosterone. Constitutively active mutations in LHR have
been identified in humans resulting in puberty in males as young as 3 or 4 years of age.
A transgenic mouse (YHR+), was generated which mimics the constitutively active LHR
by fusing the hormone, human chorionic gonadotropin, to LHR to continually activate the
receptor. Testosterone levels in YHR+ mice are high at neonatal ages. Previous studies
in the lab have shown that YHR+ mice have decreased LC numbers compared to wild
type (WT) mice. It was hypothesized that high levels of testosterone at neonatal ages was
responsible for the decrease in LC numbers and was causing a decrease in the
proliferation of LCs. To test this hypothesis, the action of testosterone was blocked with
the androgen antagonist, flutamide, and the total number of LCs as well as the number of
proliferating LCs were determined. There was no significant increase in LC number or in
proliferation of flutamide treated YHR+ mice suggesting that other factors may be
involved in the decrease in LC number.

Together, these results suggest that high

neonatal testosterone is not sufficient to inhibit LC development.
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Introduction

Gonadotropins

The gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone (FSH) are
secreted from the anterior lobe of the pituitary gland at puberty. After being released by
the pituitary gland, the hormones have influence upon the male and female gonads (1).
In males, binding of LH to its receptors, expressed in the Leydig cells within the testes is
required for testosterone production. Testosterone along with FSH stimulation of the
Sertoli cells is essential for sperm production and maturation (Fig. 1). Leydig cells,
found in the interstitium of the testis are specialized cells that develop during puberty and
start as progenitor Leydig cells (PLC) at 10 days of age in the mouse. These cells
proliferate and differentiate into immature Leydig cells (ILC) at about 35 days of age,
and adult Leydig cells (ALC) at about 56 days of age (Fig. 2). PLCs are spindle shaped
and are found close to the seminiferous tubule. PLCs develop into ILCs, which move
away from the seminiferous tubule. As it develops it acquires more smooth endoplasmic
reticulum as well as cytoplasmic lipid droplets which both act to maintain the integrity of
the cell and cause it to become more round shaped. ALCs, the largest of the Leydig cells
are round because of their high smooth endoplasmic reticulum content although they
contain no cytoplasmic lipid droplets. ALCs are responsible for the production of
testosterone (2,3). Without the production of testosterone, these mice would be
incompetent in producing offspring. The hormones LH, FSH, and testosterone are
important for Leydig cell development.
1

The Yoked Hormone Receptor Transgenic Mouse (YHR+)

In humans, a mutation can occur that causes the LH receptor to be constitutively active,
even in the absence of LH. This causes testosterone to be produced even before puberty.
This mutation can lead to a male reaching puberty at an age as young as 3 or 4 years. A
transgenic mouse, called the YHR+ mouse, was generated which mimics the
constitutively active LH receptor by using the hormone, human chorionic gonadotropin
(hCG) to continually activate the LH receptor and cause precocious puberty to occur (4)
(Fig. 3). hCG is homologous to LH and can bind to the LH receptor to activate it.
Previous studies in the lab have shown that these mice exhibit high levels of testosterone
as early as 10 days of age but a low number of Leydig cells compared to wild type (WT)
mice (Fig. 4). This reduction in the number of Leydig cells is due to a decrease in
proliferation of PLCs at 10 days and 2 weeks of age. This YHR+ mouse provides a model
to study the hormonal regulation of Leydig cell development. In WT mice, a significant
testosterone increase occurs at 5 weeks, whereas in the YHR+ mouse, the increase occurs
at 10 days. It is hypothesized that the high levels of testosterone at an inappropriate time
causes a decrease in Leydig cell number. In this study, I have tested this hypothesis by
blocking the action of testosterone with the androgen receptor antagonist, flutamide and
determining its effect on Leydig cell numbers and proliferation.
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releasing-hormone
hormone (GnRH) is secreted from the hypothalamus
Figure 1. Gonadotropin-releasing
and acts upon the pituitary which releases luteinizing hormone (LH) and follicle
stimulating hormone (FSH) which act upon the Leydig cells and Sertoli cells,
respectively. Testosterone is then released from Leydig cells and stimulates the Sertoli
cells along with FSH to aid in sperm production and maturation. Testosterone exhibits
negative feedback on the pituitary and the hypothalamus.
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development.
Figure 2. Leydig cell development
Step 1 represents the progression from PLC to ILC while step 2 represents the
progression of ILC into ALC. PLCs are spindle shaped and become rounded as they
progress into ILCs. ILCs and ALCs are both round and cannot be distinguished
morphologically. Adapted from Benton et al. (3).
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Figure 3. Schematic illustration of the yoked hormone receptor (YHR).
Human chorionic gonadotropin (hCG) fused to the luteinizing hormone receptor
(LHR) activates it continuously.

5

Figure 4. A decrease in Leydig cell number is seen in YHR+ mice at 5, 8 and 12
weeks of age (n=5). Data from Coonce et al. (5).
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Goals of the Study

1.) To block the action of testosterone with the androgen receptor antagonist,
flutamide and determine its effect on Leydig cell numbers.
YHR+ were previously found to express high levels of testosterone beginning at 10 days
of age whereas WT mice exhibit a similar increase at 5 weeks of age. These YHR+ mice
also have been found to have a lower number of LC than the WT mice. In order to
determine whether this high level of testosterone at neonatal ages in the YHR+ mice is the
cause of the low number of LC, testosterone action was blocked with the androgen
receptor antagonist, flutamide, to examine its effects on LC numbers.

2.) To analyze the number of proliferating Leydig cells in the YHR+ vehicle and
flutamide treated animals to determine whether testosterone plays a role in
proliferation.
YHR+ mice exhibit high levels of neonatal testosterone and a low number of Leydig
cells. To determine whether the high levels of testosterone at this inappropriate time is
causing a decrease in LC proliferation, YHR+ mice who had been treated with androgen
antagonist were compared to control YHR+ mice and the percent of proliferating LC were
determined for each group.
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Experimental Methods

Animal care and treatment
All animal studies were approved by the Institutional Animal Care and Use Committee at
SIU. Mice were maintained in a conventional colony with a 12h light, 12h dark cycle
and fed a standard laboratory chow and tap water ad libitum. Mice were euthanized by
CO2 asphyxiation and tissues were harvested.

Treatment of YHR+ mice with flutamide and vehicle control
In effort to determine whether blocking the action of testosterone with flutamide will
increase the number of Leydig cells, it was first necessary to determine the optimal dose
of flutamide that was effective in blocking the action of testosterone. To do this,
50µg/animal·day of flutamide was injected subcutaneously above the shoulders into male
YHR+ mice on day 7, 8 and 9 to ensure the blockage of testosterone before the time
period of PLC proliferation. This dose was chosen based on a previous study (6). The
mice were dissected on day 10 and the effectiveness of the dose was determined by
weighing the seminal vesicles. The YHR+ mice were injected subcutaneously above the
shoulders from day 7 through day 14 with 50µg/animal·day of flutamide. Another set of
YHR+ mice were treated with the vehicle control (sesame oil). The treatments occurred
at these ages because Leydig cells begin to develop around day 10 and testosterone
increased in YHR+ mice at day 10.
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Experimental Setup:
YHR+ mice were treated with vehicle and flutamide starting at 7 days of age and were
dissected on day 10, weeks 2, 3, 5, and 8 and their testes were collected. The testes were
fixed in Bouin’s solution, embedded in paraffin, and serial sections (5 µm) were obtained
where sections on each slide were 25 µm apart. The sections were then stained using an
antibody specific for 3β hydroxysteroid dehydrogenase 1 (3βHSD1), which is specific for
Leydig cells. Blocking of endogenous peroxidase was done by using 3% hydrogen
peroxide in methanol for 30 min. The sections were then incubated with normal goat
blocking serum over night. The sections were then incubated with the primary antibody
against 3βHSD1 at a dilution of 1:4000 for 1 h. Sections were then incubated in
biotinylated secondary antibody for 10 min. Vectastain® Elite ABC reagent was then
used to incubate the sections for 10 min followed by diaminobenzidine which is used to
visualize the antibody-antigen complexes that had formed. Hematoxylin was then used
to counterstain the sections (Fig. 5).

Quantification of Leydig cells:
5 areas in different parts of each section on each slide were randomly chosen and
photographed at a magnification of 400X (Fig. 6). Only the Leydig cells that were stained
with 3βHSD1 were counted within each area. Leydig cells were counted in sections that
were 5µm in depth and were 25µm apart. To determine the number of Leydig cells per
testis, the weight of the testis was used as an approximation of the testis volume because
the density of the testis is approximately 1mg/ml (7). The weight was multiplied by the
quotient of the total number of Leydig cells counted in a defined volume of 0.0047mm3.
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This volume was calculated by multiplying th
thee area of the box by the thickness of the
section (5 µm), and multiplying this number by the total number of boxes that were
counted per testis.

Quantificationn of Proliferating Leydig cells
YHR+ mice were injected from 77-13 days of age with either vehicle control or
50µg/animal·day of flutamide subcutaneously and with bromodeoxyuridine (BrdU),
(BrdU)
intraperitoneally, 2h prior to sacrifice at day 14. Testes were fixed in bouins solution,
solution
embedded and serial sectioned (5 µm). Immunofluorescence staining was
as performed with
antibodies against BrdU to mark the proliferating cells and 33βHSD1
HSD1 to mark Leydig
cells. Endogenous peroxidase was blocked by incubating slides in 3% hydrogen peroxide
for 30 min. Sections were then incubated in normal goat serum for 1 h and then were
incubated over night in the primary antibody against 3βHSD1 in a 1:4000 dilution.
Sections were then incubated in biotinylated secondary antibody for 1 h followed by
incubation in streptavidin 594 in a 1:200 dilution for 30 min. The sectio
sections
ns were then
incubated in Vector® M.O.M.™
.O.M.™ Mouse Ig Blocking Reagent for 3 h followed by
incubation with a primary antibody against BrdU in a 1:100 dilution for 1 h. The sections
were then incubated in the secondary antibody against DK
DKαms
ms 488 in a 1:200 dilution
di
for
1 h. The slide was then mounted with a mounting medium with dapi. The number of
BrdU and 3βHSD1
HSD1 positive cells was quantified and expressed as a percent of the total
number of 3βHSD1
HSD1 positive LCs.
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Figure 5.. Experimental Setup
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Figure 6. Sections of testis were stained with an antibody specific for 33βHSD1
βHSD1 to mark
Leydig cells.
A. Whole testis section with boxes representing areas of counted Leydig cells.
B. Higher magnification at 400x of a representative box showing PLC and ALC.
12

Results and Discussion
The weight of the seminal vesicles of the YHR+ mice, which have been treated with
flutamide were compared to the weight of the seminal vesicles from WT mice and YHR+
mice that have been treated with only vehicle. Because the seminal vesicles respond to
androgens and become larger in the presence of testosterone, if the action of testosterone
is blocked effectively, the weight of the YHR+ seminal vesicles treated with flutamide
should be similar to those of the WT mice. The weight of the seminal vesicles indicated
that testosterone was blocked effectively at 2 and 3 weeks of age (Fig. 7). At both 2 and
3 weeks of age, the weight of the flutamide treated YHR+ mice was significantly lower
than the vehicle YHR+ mice and was comparable to the seminal vesicle weight of the WT
mice at 3 weeks. This suggests that the effect of testosterone was effectively blocked at
these ages. By 5 weeks there was no significant difference in the weight of the seminal
vesicles in the vehicle WT, vehicle YHR+ and flutamide treated YHR+ mice. This
suggests that the effect of the androgen antagonist flutamide had worn off and
testosterone was able to exert its normal effects by this age. This increase in testosterone
effects at 5 weeks is desired because in the WT mouse a large increase of testosterone is
seen at 5 weeks and is considered normal.
After quantification of LCs at 2, 3, 5 and 8 weeks of age, no significant difference
in the number of LCs was seen at 2 or 3 weeks of age (Fig. 8). The number of LC was
not significantly altered in the flutamide treated YHR+ mice compared to vehicle treated
YHR+ mice. This suggests that high levels of testosterone at neonatal ages are not
sufficient to inhibit the development of LC. However the general trend is that the
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number of LC in the flutamide treated YHR+ mice is higher than that of the vehicle
YHR+ mice although not significantly higher. This suggests that testosterone may play a
role in the development of LCs along with other factors.
No significant difference was found when comparing the flutamide treated YHR+
mice to the vehicle treated YHR+ mice at 2 weeks of age. This data suggests that the
high levels of neonatal testosterone did not cause a decrease in LC proliferation (Fig. 9).
Other factors may be involved in the proliferation of LC in addition to testosterone.
Further study is needed to determine which factors are contributing to LC
development and proliferation in the YHR+ mice. It has been found that FSH levels are
significantly lower in YHR+ mice compared to WT mice (4). FSH could be a
contributing factor to the low numbers of LC seen in YHR+ mice and should be studied to
determine this. Another possible factor contributing to the difference in LC number
could be IGF-1. IGF-1 is important for LC development and when suppressed, results in
reduced numbers of LC (8). Testosterone is known to increase IGF-1 (9). Therefore,
because we are blocking the action of testosterone in the flutamide treated YHR+ mice,
IGF-1 levels are likely to be decreased which could combat the expected increase in LC
numbers. Because it is not known whether or not IGF-1 levels are altered in the YHR+
mice, it would beneficial to determine IGF-1 levels the future.
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Figure 7. Data represent mean ± SEM (n=5) and were analyzed by one
one-way
way ANOVA.
Different letters indicate significant differences between treatment groups (p<0.05).
(p<0.0

15

Figure 8. Data are expressed as mean ± SEM and were analyzed by one-way
way ANOVA
(n=5). Different letter assignments indicate significant di
difference
fference in treatment groups.
(p<0.05)
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Figure 9. Data are expressed as mean ± SEM and were analyzed by t test (n=4-5).
Different letter assignments indicate significant difference in treatment groups. (p<0.05)
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